• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.

作者信息

Moulder Stacy, Moroney John, Helgason Thorunn, Wheler Jennifer, Booser Daniel, Albarracin Constance, Morrow Phuong K, Koenig Kimberly, Kurzrock Razelle

机构信息

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

J Clin Oncol. 2011 Jul 1;29(19):e572-5. doi: 10.1200/JCO.2010.34.0604. Epub 2011 Apr 11.

DOI:10.1200/JCO.2010.34.0604
PMID:21482991
Abstract
摘要

相似文献

1
Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.脂质体阿霉素、贝伐单抗和替西罗莫司治疗乳腺化生性癌的反应：生物学原理及对乳腺癌干细胞研究的启示
J Clin Oncol. 2011 Jul 1;29(19):e572-5. doi: 10.1200/JCO.2010.34.0604. Epub 2011 Apr 11.
2
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.抑制磷酸肌醇3-激酶通路用于治疗转移性化生性乳腺癌患者。
Ann Oncol. 2015 Jul;26(7):1346-52. doi: 10.1093/annonc/mdv163. Epub 2015 Apr 15.
3
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.曲妥珠单抗联合多西他赛和卡培他滨新辅助治疗 HER2-局部晚期乳腺癌的Ⅱ期临床试验：美国国家综合癌症网络基金会研究组的研究。
Clin Breast Cancer. 2011 Aug;11(4):228-34. doi: 10.1016/j.clbc.2011.04.001. Epub 2011 May 4.
4
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.贝伐单抗联合替西罗莫司与脂质体多柔比星治疗的抗血管生成抗体的 I 期研究：耐受性和生物学活性。
Clin Cancer Res. 2012 Oct 15;18(20):5796-805. doi: 10.1158/1078-0432.CCR-12-1158. Epub 2012 Aug 27.
5
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.在多柔比星和环磷酰胺之后，曲妥珠单抗联合紫杉醇用于可手术的HER2阳性乳腺癌。
Oncologist. 2006 May;11(5):533; author reply 534. doi: 10.1634/theoncologist.11-5-533.
6
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.非聚乙二醇化脂质体阿霉素联合曲妥珠单抗治疗HER2阳性乳腺癌患者的I期研究
Clin Breast Cancer. 2009 May;9(2):101-7. doi: 10.3816/CBC.2009.n.019.
7
[Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].[人表皮生长因子受体2阳性乳腺癌的诊断与治疗：中国抗癌协会专家共识]
Zhonghua Zhong Liu Za Zhi. 2010 Feb;32(2):158-60.
8
[Trastuzumab for treatment of advanced breast cancers].曲妥珠单抗用于治疗晚期乳腺癌
Nihon Rinsho. 2000 Apr;58 Suppl:340-4.
9
Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.贝伐单抗与紫杉醇用于治疗伴有中枢神经系统转移的乳腺癌患者：病例系列
Clin Breast Cancer. 2009 May;9(2):118-21. doi: 10.3816/CBC.2009.n.021.
10
[Molecular subtypes and individualized treatment of breast cancer].[乳腺癌的分子亚型与个体化治疗]
Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):641-4.

引用本文的文献

1
Survival outcomes after systemic treatment of high-grade triple-negative metaplastic breast cancer versus triple-negative breast cancer of no special type.高级别三阴性化生性乳腺癌与非特殊类型三阴性乳腺癌全身治疗后的生存结局
Virchows Arch. 2025 Aug 22. doi: 10.1007/s00428-025-04224-0.
2
Translational Aspects in Metaplastic Breast Carcinoma.化生性乳腺癌的转化研究方面
Cancers (Basel). 2024 Apr 7;16(7):1433. doi: 10.3390/cancers16071433.
3
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation.
靶向VEGFR2的阿霉素免疫脂质体与NK细胞激活协同增强抗肿瘤和抗转移作用。
Invest New Drugs. 2023 Oct;41(5):664-676. doi: 10.1007/s10637-023-01372-5. Epub 2023 Aug 5.
4
Metaplastic Breast Carcinoma in U.S. Population: Racial Disparities, Survival Benefit of Adjuvant Chemoradiation and Future Personalized Treatment with Genomic Landscape.美国人群中的化生性乳腺癌：种族差异、辅助放化疗的生存获益以及基于基因组图谱的未来个性化治疗
Cancers (Basel). 2023 May 28;15(11):2954. doi: 10.3390/cancers15112954.
5
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).多中心二期临床试验：依匹单抗联合纳武利尤单抗治疗不可切除或转移性间变性乳腺癌：双重抗 CTLA-4 和抗 PD-1 阻断在罕见肿瘤中的队列 36（DART，SWOG S1609）。
Clin Cancer Res. 2022 Jan 15;28(2):271-278. doi: 10.1158/1078-0432.CCR-21-2182. Epub 2021 Oct 29.
6
A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma.安罗替尼治疗晚期乳腺化生性癌1例报告
Onco Targets Ther. 2021 Aug 27;14:4599-4607. doi: 10.2147/OTT.S318645. eCollection 2021.
7
Construction and validation of prognostic nomogram for metaplastic breast cancer.构建和验证化生性乳腺癌的预后列线图。
Bosn J Basic Med Sci. 2022 Feb 1;22(1):131-139. doi: 10.17305/bjbms.2021.5911.
8
Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges.靶向多种恶性肿瘤中的信号通路网络：进展与挑战
Front Pharmacol. 2021 May 31;12:675675. doi: 10.3389/fphar.2021.675675. eCollection 2021.
9
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.三阴性乳腺癌特殊组织学亚型患者辅助化疗的获益：一项系统评价。
Breast Cancer Res Treat. 2021 Jun;187(2):323-337. doi: 10.1007/s10549-021-06259-8. Epub 2021 May 27.
10
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.化生性乳腺癌中的端粒酶逆转录酶（TERT）启动子热点突变与基因扩增
NPJ Breast Cancer. 2021 Apr 16;7(1):43. doi: 10.1038/s41523-021-00250-8.